Monday's session: gap up and gap down stock in the S&P500 index
By Mill Chart
Last update: Sep 19, 2022
Let's have a look at the S&P500 gap up and gap down stocks in today's session.
Gap down stocks
| Ticker | Change | Comment |
|---|---|---|
| MRNA | -8.73% | MODERNA INC's (NASDAQ:MRNA) stock price decreased by 8.73% to $125.72 with a gap of 10.17%. In the last 6 months the share price dropped with 23.02%. |
| MKTX | -6.12% | MARKETAXESS HOLDINGS INC's (NASDAQ:MKTX) shares fell 6.12% to $236.68 during Monday's session with a gap of 9.33%. In the last 6 months the share price dropped with 28.75%. |
| EW | -4.87% | EDWARDS LIFESCIENCES CORP's (NYSE:EW) stock price decreased by 4.87% to $88.8 with a gap of 5.94%. Shareholders saw the stock price going 21.83% lower is the past year. |
| ALGN | -4.77% | ALIGN TECHNOLOGY INC's (NASDAQ:ALGN) stock price is declining with 4.77% to a price of $237.13 with a gap of 5.28%. In the last 6 months the stock lost 43.77%. |
| DXCM | -4.71% | DEXCOM INC's (NASDAQ:DXCM) stock price decreased by 4.71% to $85.85 with a gap of 5.32%. The stock is trading 30.93% higher than 3 months ago. |
| OGN | -3.7% | ORGANON & CO's (NYSE:OGN) stock price decreased by 3.7% to $27.55 with a gap of 4.84%. |
| TFX | -3.66% | TELEFLEX INC's (NYSE:TFX) stock price is declining with 3.66% to a price of $219.02 with a gap of 5.41%. The stock is trading 35.03% lower than 6 months ago. |
| LLY | -3.55% | ELI LILLY & CO's (NYSE:LLY) shares fell 3.55% to $297.92 with a gap of 4.5%. In the last year the stock gained 34.24%. |
| VRTX | -3.32% | VERTEX PHARMACEUTICALS INC's (NASDAQ:VRTX) shares fell 3.32% to $280.1 with a gap of 4.2%. Shareholders saw the stock price going 53.86% higher is the past year. |
| ABMD | -3.22% | ABIOMED INC's (NASDAQ:ABMD) shares fell 3.22% to $250.34 with a gap of 4.23%. The stock is trading 27.14% lower than a year ago. |
For the full top loser list go to our gap down stocks screener.
VERTEX PHARMACEUTICALS INC
NASDAQ:VRTX (4/16/2024, 4:41:22 PM)
After market: 394.17 0 (0%)394.17
-3.19 (-0.8%)
VRTX News
a day ago - The Motley FoolHere's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals StockVertex just laid claim to an asset that might be very valuable.
Vertex just laid claim to an asset that might be very valuable.
4 days ago - The Motley FoolCould This Stock Be the Next Biotech Buyout?Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
4 days ago - Investor's Business DailyStock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly ReviewThe stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.
5 days ago - InvestorPlaceWall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.
5 days ago - InvestorPlaceRaymond James Just Raised Its Price Target on Nvidia (NVDA) StockNvidia stock is on the move Thursday after shares of NVDA got an increased price target of $1,100 from Raymond James analysts.
5 days ago - InvestorPlaceApple Spyware Warning: What to Know About ‘Mercenary Spyware Attack’ AlertsAn Apple spyware warning has been sent to iPhone owners in 92 states as they have been targeted by a mercenary spyware attack.
5 days ago - InvestorPlaceThe $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% TodayVertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
5 days ago - Investor's Business DailyBiotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsNovartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.
5 days ago - The Motley FoolVertex Pharmaceuticals: Buy, Sell, or Hold?The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run?
6 days ago - Investor's Business DailyVertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion DealThe companies expect the deal to close later this quarter.
6 days ago - BloombergVertex to Buy Kidney Disease Drug Developer for $4.9 BillionVertex Pharmaceuticals Inc. agreed to buy Alpine Immune Sciences Inc. for a total equity value of about $4.9 billion, adding the biotech company’s immune treatments to its growing pipeline.
